5-Bromo-2-chloro-3-nitropyridine | CAS:67443-38-3

We serve 5-Bromo-2-chloro-3-nitropyridine CAS:67443-38-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-Bromo-2-chloro-3-nitropyridine

Chemical Name:5-Bromo-2-chloro-3-nitropyridine
CAS.NO:67443-38-3
Synonyms:5-bromo-2-chloro-3-nitropyridine;
Molecular Formula:C5H2BrClN2O2
Molecular Weight:237.43900
 
Physical and Chemical Properties:
Density:1.936;
Melting point:64-69oC;
Boiling point:285.4oC;
Flash point:126.4oC;
Index of Refraction:1.627;
 
Specification:
Appearance:Yellow to light brown crystalline powder
Purity(GC):≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis
 



Contact us for information like 5-Bromo-2-chloro-3-nitropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-2-chloro-3-nitropyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-2-chloro-3-nitropyridine Use and application,5-Bromo-2-chloro-3-nitropyridine technical grade,usp/ep/jp grade.


Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate manufacturer With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.9-Bromo-10-(1-Naphthalenyl)Anthracene vendor Domestic API companies cooperate with major international companies through commissioned processing, patent transfer, and joint venture production.At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.